PluriSIn #1 (NSC 14613)
(Synonyms: NSC 14613) 目录号 : GC17107
A selective inhibitor of stearoyl-CoA desaturase
Cas No.:91396-88-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NSC 14613 is a pluripotent cell-specific inhibitor (PluriSIn) that selectively eliminates human pluripotent stem cells (hPSCs) leaving a large array of progenitor and differentiated cells unaffected. Among 15 identified PluriSIns, NSC 14613 (also known as PluriSIn #1) is a derivative of N-acyl phenylhydrazine that shares a common structure moiety, phenylhydrazine (Ph-N[H,C]-NH) with 9 other PluriSIns. NSC 14613 is also an inhibitor of stearoyl-coA desaturase (SCD1) that inhibits the activity of SCD1 in hPSCs causing the imbalance between substrates and products and subsequently resulting in the accumulation of palmitate and stearate and the deprivation of oleate. Study results have suggested that NSC 14613 is able to induce ER stress, protein synthesis attenuation and apoptosis in hPSCs and can be used to prevent teratoma formation from tumorigenic undifferentiated cells.
Reference
[1].Ben-David U, Gan QF, Golan-Lev T, Arora P, Yanuka O, Oren YS, Leikin-Frenkel A, Graf M, Garippa R, Boehringer M, Gromo G, Benvenisty N. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79
Cell experiment: | The differentiation of iPS cells to cardiomyocytes (CM) is induced by embryoid body (EB) formation. When iPS cells reached 70% confluency in 10-cm dishes, cells are digested using 0.25% trypsin/EDTA. Cell pellets are re-suspended in differentiation medium (DMEM with 20% FBS and 10 ng/mL BMP4) to a final concentration of 200,000 cells/mL. Cell suspensions are added to 6-well plates with Ulta-Low Attachment surfaces for 4 d to initiate EB formation. On day 5, EBs are cultured on 0.1% gelatin-coated dishes for 14 d using CF culture medium for the outgrowth of cardiac structures. At this stage, iPS cells undergoing EB formation are termed iPS derivates (iPSD)[1]. |
References: [1]. Zhang L, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. | |
| Cas No. | 91396-88-2 | SDF | |
| 别名 | NSC 14613 | ||
| 化学名 | N'-phenylpyridine-4-carbohydrazide | ||
| Canonical SMILES | C1=CC=C(C=C1)NNC(=O)C2=CC=NC=C2 | ||
| 分子式 | C12H11N3O | 分子量 | 213.24 |
| 溶解度 | ≥ 6.75 mg/mL in DMSO, ≥ 15.67 mg/mL in EtOH with ultrasonic and warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.6896 mL | 23.4478 mL | 46.8955 mL |
| 5 mM | 0.9379 mL | 4.6896 mL | 9.3791 mL |
| 10 mM | 0.469 mL | 2.3448 mL | 4.6896 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet